Search
C4 Therapeutics Inc
CCCCAdd to Watchlist
4.300USD
-0.040-0.92%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
447.36MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of C4 Therapeutics Inc is 8.75, ranking 63 out of 387 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 29.00 and a low of 6.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.333
Target Price
+207.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
C4 Therapeutics Inc
CCCC
7
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is C4 Therapeutics Inc's expected revenue for the next quarter?
C4 Therapeutics Inc's expected revenue is 4.00M.
What is C4 Therapeutics Inc's price target?
Analysts forecast that C4 Therapeutics Inc's price target is USD 10.00, with the highest forecast at USD 29.00 and the lowest forecast at USD 6.00.
How have C4 Therapeutics IncCCCC's recent earnings per share performed?
The market expectation was USD -0.20, while C4 Therapeutics IncCCCC's earnings per share (EPS) for the previous quarter was USD -1.27. EPS for the next quarter is expected at USD -0.23.
What is the analyst rating for C4 Therapeutics Inc?
Based on the ratings of C4 Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.